Page 33 - Sun Pharma News Today

Beyond thematic indices, strategy indices that focus on low volatility have also outperformed Nifty 50 returns. For example, the Nifty 100 Low Volatility Index has gained 41 percent in one year, but its volatility reading was at 8.84

Reliances GRMs are currently at about $7.4 versus about $5.5 in the previous quarter. That is going to be a positive trigger. In the telecom business, the ARPU is steadily growing. InterGlobe Aviation is mirroring HDFC Banks past. Uno Minda and Motherson Sumi show promise in the EV space. IndiGo dominates market share. Pharma sector sees growth potential.

In FY23, 30 companies undertook voluntary product recalls, while 16 were forced to recall their products, shows data sourced from Prime Database. Product recall information forms part of the business responsibility and sustainability reporting (BRSR) framework that is mandatory disclosure for the top 1,000 listed companies from FY23. Since many companies have not disclosed data for FY22, a YoY comparison is not tenable.

According to analysts, profit-taking may resume until the index decisively reclaims 22,200.

Deven Choksey discusses the positive trajectory of Adani Ports, Torrent Pharmas strategic growth approach, and Tata Consumers market readiness. The evolving market dynamics favor strategic expansions and operational stability for these key players. Choksey further says that automobile ancillaries give a good amount of opportunity at this point of time.

Nifty opened on a negative note and slowly crawled inside the positive territory. It remained there at close.

Last week, the State Bank of India (SBI) disclosed data on the now-defunct electoral bonds (EBs) in two sets. Purchasing these bonds was voluntary; however, which entrepreneur would willingly part with their hard-earned money for grasping, self-serving politicians? They do so under coercion or incentives.

Indian drug manufacturers are utilizing flagship products or "mother brands" to introduce new combinations and establish leadership in therapy areas, as per research by Pharmarack. For example, USVs anti-diabetes drug Glycomet has bolstered the companys reputation in diabetic therapy and facilitated partnerships with multinational drugmakers for innovative therapies.

Pediatric atopic dermatitis (AD) is associated with greater odds of reported difficulties in learning and memory.

With Indians reporting the onset of diabetes, heart disease at least a decade earlier than other populations, these drugs could change the map of non-communicable diseases in India